**Title (Not Abbreviations, Initial Letters Uppercase, Bold)**

Name SURNAME1\*[](https://orcid.org/), Name SURNAME2[](https://orcid.org/)

1 XXX University, Faculty of XXX, Department of XXX, Zip Code, City, Country

2 XXX University, Faculty of XXX, Department of XXX, Zip Code, City, Country

\*Corresponding Author: Name Surname, e-mail:

**ABSTRACT:** The abstract should present as much as possible of the qualitative and quantitative information contained in the paper yet it should be brief (100 - 250 words), specific and self-contained.

**Keywords:** *provide* *between 3 and 6 piece*

# INTRODUCTION

Times New Roman and 12 points, “1.5” spacing, justified [1,2].

# MATERIAL AND METHOD

Times New Roman and 12 points, “1.5” spacing, justified [1,2].

## **Example Subtitle**

Times New Roman and 12 points, “1.5” spacing, justified [1,2].

# RESULT

Times New Roman and 12 points, “1.5” spacing, justified [1,2].

# DISCUSSION

Times New Roman and 12 points, “1.5” spacing, justified [1,2].

**Table 1.**Times New Roman and 11 points, “1.5” spacing, align left.

|  |  |  |
| --- | --- | --- |
| Xxx\* | Xxx | Xxx |
| 1 | 15 | 22±2 |
| 2 | 17 | 33±3 |

\* Contents of the table can be 10 points, “1” spacing. Explanation should be 9 font size, 1 range. There should not be any space between the end of the table and the explanation.

**Figure 1**. Times New Roman and 11 points, “1.5” spacing, align left.

# ACKNOWLEDGEMENTS

Times New Roman and 12 points, “1.5” spacing, justified [1,2].

# AUTHOR CONTRIBUTIONS

Hypotesis: Y.N., M.B.; Design: Y.N.Z., Y.Y.; Literature review: B.A., İ.A. K.A.; Data Collection: Z.Ö., K.B.; Analysis and/or interpretation: C.V.Z., M.A.A.; Manuscript writing: Y.Y., M.B.A., Y.N.Z.

# CONFLICT OF INTEREST

In the conflict of interest section, if there is no conflict of interest, the “Authors declare that there is no conflict of interest.” statement should be included.

Times New Roman and 12 points, “1.5” spacing, justified [1,2].

# REFERENCES

[1] Popat A, Liu J, Lu GQM, Qiao SZ. A pH-responsive drug delivery system based on chitosan coated mesoporous silica nanoparticles. *Journal of Materials Chemistry*, 2012; **22**(22): 11173-78.

[2] Hall JE. *Guyton ve Hall Tıbbi Fizyoloji. 12. bs.(Çev. Ed. Berrak Çağlayan Yeğen)*. 2013, Elsevier/Nobel Tıp Kitabevleri.